2025 ASCO GI | 中国肝胆胰领域研究速递

Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE).

经动脉化疗栓塞（TACE）联合卡瑞利珠单抗和阿帕替尼对比单纯TACE治疗符合栓塞条件的不可切除肝细胞癌：一项多中心、开放标签、随机、II期研究（CAP-ACE） 

讲者：滕皋军    东南大学附属中大医院

MRI imaging and machine learning based radiomics for detection of mixed HCC and CCA tumors: Still a need for liver biopsy? 

讲者：Yuquan Qian    中国医学科学院肿瘤医院

Development and validation of the SPEAR scoring model and predicting overall survival in unresectable hepatocellular carcinoma patients treated with TACE, molecular targeted therapies, and immune checkpoint inhibitors.

讲者：Wenli Li    南方医科大学南方医院

Regorafenib combined with immunotherapy and prognosis of unresectable hepatocellular carcinoma.

讲者：Tianxiang Li    青岛大学附属医院

Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023).    

讲者：Rong Yan    东南大学附属中大医院

Comparison of efficacy and safety of PD-1 and PD-L1 antibodies in combination with hepatic arterial infusion chemotherapy and target therapy for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study.    

讲者：Xinhao Xiong    中山大学肿瘤防治中心

A global comparative study on MDT practices in the management of hepatocellular carcinoma in high-income countries (HICs) and low- and middle-income countries (LMICs).

讲者：Huang Zhiyong    华中科技大学同济医学院附属同济医院

Leading the way: How leading Chinese institutions drive MDT excellence in hepatocellular carcinoma.    

讲者：Jiaping Li    中山大学附属第一医院 

Prompt initiation of durvalumab and tremelimumab treatment for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B.       

讲者：Yu-Yun Shao    台湾大学医学院附设医院 

Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial).    

讲者：匡铭    中山大学附属第一医院

Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection.

讲者：Yiwen Chen    浙江大学医学院附属第一医院

First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses.  

讲者：赵明    中山大学肿瘤防治中心

First-line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE-H-106 study.   

讲者：毕锋    四川大学华西医院

Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma.      

讲者：Feng Shi    广东省人民医院

Selective internal radiation therapy with yttrium-90 resin microspheres followed by lenvatinib plus PD-1 inhibitor for large or huge advanced-stage hepatocellular carcinoma: A retrospective cohort study from China.    

讲者：Jingjun Huang    广州医科大学附属第二医院

Current status of physicians’ perception of HCC conversion/downstaging therapy: A nationwide survey in China.    

讲者：Xinyu Bi    中国医学科学院肿瘤医院

Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.    

讲者：Zheng Wu    西安交通大学第一附属医院

Surufatinib combined with locoregional therapies and immune checkpoint inhibitor (ICI) for treating unresectable or metastatic intrahepatic cholangiocarcinoma.    

讲者：Wan Guang Zhang    华中科技大学同济医学院附属同济医院

Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer.    

讲者：Haobin Yu    中国科学技术大学附属第一医院

Long-term survival outcomes of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma.    

讲者：Ching-Tso Chen    台湾大学医学院附设医院新竹台大分院

Updated results of ALTER-H006: A phase II study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.    

讲者：Xianhai Mao    中南大学湘雅医学院附属肿瘤医院

Association of GPR120 and NGF with perineural invasion in cholangiocarcinoma: Clinical and experimental insights.    

讲者：Jun He    苏州大学附属第一医院

Exploring Nectin-4 expression in hepatocellular carcinoma.

讲者：Chien Huai Chuang    台湾大学癌症中心

Efficacy and safety of surufatinib in unresectable or metastatic grade 3 pancreatic neuroendocrine tumors (NET G3): Real-world analysis.     

讲者：Jian Wang    山东大学齐鲁医院

The value and indications for surgery in pancreatic cancer with synchronous liver metastases.    

讲者：Ruili Wei    中日友好医院  

Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine/nab-paclitaxel as first-line (1L) treatment in patients with Claudin18.2-positive locally advanced unresectable or metastatic (LA/m) pancreatic cancer.  

讲者：刘福囝    中国医科大学附属第一医院 

The effect of renin-angiotensin system inhibitors on patients with pancreatic cancer receiving systemic treatment: A retrospective cohort study from TriNetX US collaborative networks.  

讲者：Cheng-Wei Chou    台中荣民总医院

Surufatinib combined with TAS-102 as a late-line therapy in patients with metastatic pancreatic cancer (mPDAC): Updated results of a single-arm, phase II trial. 

讲者：张东生    中山大学肿瘤防治中心 

Chidamide plus envafolimab combined with S-1 as second-line treatment in advanced and metastatic pancreatic cancer (P-henomS/SCOG-P002): A single-arm, exploratory, multicenter, phase 2 trial—Interim report.    

讲者：Wei Li    苏州大学附属第一医院

Personalized ctDNA monitoring to assess the recurrence of early stage pancreatic cancer after surgery.    

讲者：杜娟    南京鼓楼医院

AMBER part 2F: Cobolimab in combination with dostarlimab in treatment-naïve patients with locally advanced/metastatic and/or unresectable hepatocellular carcinoma (HCC).    

讲者：Stephen Lam Chan    香港中文大学